{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:20:14Z","timestamp":1753521614854,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s13318-024-00927-y","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T04:38:49Z","timestamp":1732682329000},"page":"53-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the Clinical Outcomes of Cyclosporine Short Infusion Versus Continuous Infusion Postallogenic Stem Cell Transplantation"],"prefix":"10.1007","volume":"50","clinical-trial-number":[{"clinical-trial-number":"nct04575779","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0020-7514","authenticated-orcid":false,"given":"Shaymaa M. M.","family":"El-Awady","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7032-0413","authenticated-orcid":false,"given":"Amal M.","family":"El Afifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8632-0608","authenticated-orcid":false,"given":"Rania","family":"Afifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2611-4853","authenticated-orcid":false,"given":"Nagwa A.","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-9523","authenticated-orcid":false,"given":"Marwa Adel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"927_CR1","unstructured":"Khaddour K, Hana CK, Mewawalla P. Hematopoietic Stem Cell Transplantation. In Treasure Island (FL); 2021."},{"issue":"10","key":"927_CR2","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","volume":"54","author":"RF Duarte","year":"2019","unstructured":"Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019;54(10):1525\u201352.","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"927_CR3","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1056\/NEJM197504172921605","volume":"292","author":"E Thomas","year":"1975","unstructured":"Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975;292(16):832\u201343.","journal-title":"N Engl J Med"},{"issue":"12","key":"927_CR4","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"927_CR5","first-page":"505","volume":"22","author":"U Sahin","year":"2016","unstructured":"Sahin U, Toprak SK, Atilla PA, Atilla E, Demirer T. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. JIC. 2016;22(8):505\u201314.","journal-title":"JIC."},{"issue":"9674","key":"927_CR6","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JLM Ferrara","year":"2009","unstructured":"Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550\u201361.","journal-title":"Lancet"},{"issue":"10","key":"927_CR7","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1182\/blood-2006-12-041889","volume":"109","author":"HJ Deeg","year":"2007","unstructured":"Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109(10):4119\u201326.","journal-title":"Blood"},{"issue":"20","key":"927_CR8","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1182\/blood-2009-06-204669","volume":"114","author":"G Soci\u00e9","year":"2009","unstructured":"Soci\u00e9 G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood. 2009;114(20):4327\u201336.","journal-title":"Blood"},{"issue":"1","key":"927_CR9","first-page":"16","volume":"11","author":"J Wojnar","year":"2006","unstructured":"Wojnar J, Giebel S, Krawczyk-Kulis M, Markiewicz M, Kruzel T, Wylezol I, et al. Acute graft-versus-host disease. The incidence and risk factors. Ann Transplant. 2006;11(1):16\u201323.","journal-title":"Ann Transplant"},{"issue":"4","key":"927_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/bmt.2012.187","volume":"48","author":"SE Lee","year":"2013","unstructured":"Lee SE, Cho BS, Kim JH, Yoon JH, Shin SH, Yahng SA, et al. Risk and prognostic factors for acute GVHD based on NIH consensus criteria. Bone Marrow Transplant. 2013;48(4):587\u201392.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"927_CR11","first-page":"1","volume":"3","author":"NJ Chao","year":"1997","unstructured":"Chao NJ. Graft-versus-host disease: the viewpoint from the donor T cell. Biol Blood Marrow Transplant. 1997;3(1):1\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"927_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0301-472X(00)00677-9","volume":"29","author":"H Goker","year":"2001","unstructured":"Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol. 2001;29(3):259\u201377.","journal-title":"Exp Hematol"},{"issue":"12","key":"927_CR13","doi-asserted-by":"publisher","first-page":"5785 LP","DOI":"10.4049\/jimmunol.1390055","volume":"191","author":"JR Azzi","year":"2013","unstructured":"Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can\u2019t live without. J Immunol. 2013;191(12):5785 LP \u2013 5791.","journal-title":"J Immunol"},{"issue":"1","key":"927_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1054\/clnu.2000.0151","volume":"20","author":"P Santos","year":"2001","unstructured":"Santos P, Louren\u00e7o R, Camilo ME, Oliveira AG, Figueira I, Pereira ME, et al. Parenteral nutrition and cyclosporine: do lipids make a difference? A prospective randomized crossover trial. Clin Nutr. 2001;20(1):31\u20136.","journal-title":"Clin Nutr"},{"issue":"1","key":"927_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.bmt.1705402","volume":"38","author":"JS Choi","year":"2006","unstructured":"Choi JS, Lee SH, Chung SJ, Yoo KH, Sung KW, Koo HH. Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2006;38(1):29\u201335.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"927_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2165\/00003088-200241090-00001","volume":"41","author":"F Akhlaghi","year":"2002","unstructured":"Akhlaghi F, Trull AK. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet. 2002;41(9):615\u201337.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"927_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.bbmt.2011.11.029","volume":"18","author":"B Glotzbecker","year":"2012","unstructured":"Glotzbecker B, Duncan C, Alyea E, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant. 2012;18(7):989\u20131006.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"927_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/sj.bmt.1704374","volume":"33","author":"N Ogawa","year":"2004","unstructured":"Ogawa N, Kanda Y, Matsubara M, Asano Y, Nakagawa M, Sakata-Yanagimoto M, et al. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplant. 2004;33(5):549\u201352.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"927_CR19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/sj.bmt.1700745","volume":"19","author":"T Ruutu","year":"1997","unstructured":"Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant. 1997;19(8):759\u201364.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"927_CR20","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.4103\/sja.SJA_559_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S. The CONSORT statement. Saudi J Anaesth. 2019;13(Suppl 1):S27-30.","journal-title":"Saudi J Anaesth"},{"key":"927_CR21","doi-asserted-by":"crossref","unstructured":"Lim CY, In J. Randomization in clinical studies. Korean J Anesthesiol [Internet]. 2019 Jun 1 [cited 2022 Aug 28];72(3):221\u201332. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30929415\/","DOI":"10.4097\/kja.19049"},{"key":"927_CR22","doi-asserted-by":"crossref","unstructured":"Rosenblad A. Sample size calculations in clinical research (2nd edn). Shein-Chung Chow, Jun Shao and Hansheng Wang, Chapman & Hall\/CRC, Boca Raton, FL, 2008. No. of pages: xiv + 465 (hardcover). Price: $89.95. ISBN 1-58488-982-9. Stat Med. 2009;28(2):360.","DOI":"10.1002\/sim.3468"},{"issue":"4","key":"927_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","volume":"97","author":"PA Rowlings","year":"1997","unstructured":"Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Jean Henslee-Downey P, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855\u201364.","journal-title":"Br J Haematol"},{"issue":"1","key":"927_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/pst.1716","volume":"15","author":"L Flight","year":"2016","unstructured":"Flight L, Julious SA. Practical guide to sample size calculations: non-inferiority and equivalence trials. Pharm Stat. 2016;15(1):80\u20139.","journal-title":"Pharm Stat"},{"issue":"3","key":"927_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/jps.2600810303","volume":"81","author":"DR Luke","year":"1992","unstructured":"Luke DR, Brunner LJ, Lopez-Berestein G, Yau JC. Pharmacokinetics of cyclosporine in bone marrow transplantation: longitudinal characterization of drug in lipoprotein fractions. J Pharm Sci. 1992;81(3):208\u201311.","journal-title":"J Pharm Sci"},{"issue":"1","key":"927_CR26","first-page":"29","volume":"108","author":"K Tarwater","year":"2011","unstructured":"Tarwater K. Estimated glomerular filtration rate explained. Mol Med. 2011;108(1):29\u201332.","journal-title":"Mol Med"},{"issue":"4","key":"927_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295\u2013304.","journal-title":"Transplantation"},{"issue":"65","key":"927_CR28","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.talanta.2004.07.048","volume":"1","author":"GA Khoschsorur","year":"2005","unstructured":"Khoschsorur GA, Erwa W, Fruehwirth F, Stettin M, Meinitzer A, Hoebarth G, et al. High-performance liquid chromatographic method for the simultaneous determination of cyclosporine A and its four major metabolites in whole blood. Talanta. 2005;1(65):638\u201343.","journal-title":"Talanta"},{"issue":"7","key":"927_CR29","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.clinbiochem.2005.04.009","volume":"38","author":"P Salm","year":"2005","unstructured":"Salm P, Taylor PJ, Lynch SV, Warnholtz CR, Pillans PI. A rapid HPLC-mass spectrometry cyclosporin method suitable for current monitoring practices. Clin Biochem. 2005;38(7):667\u201373.","journal-title":"Clin Biochem"},{"issue":"382","key":"927_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00216-005-3196-2","volume":"1","author":"M Zaater","year":"2005","unstructured":"Zaater M, Tahboub Y, Najib N. Liquid chromatographic\u2013electrospray mass spectrometric determination of cyclosporin A in human plasma. Anal Bioanal Chem. 2005;1(382):223\u201330.","journal-title":"Anal Bioanal Chem"},{"issue":"37","key":"927_CR31","doi-asserted-by":"publisher","first-page":"59892","DOI":"10.18632\/oncotarget.10988","volume":"7","author":"S Park","year":"2016","unstructured":"Park S, Kim K, Jang JH, Kim SJ, Kim WS, Jung CW. Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation. Oncotarget. 2016;7(37):59892.","journal-title":"Oncotarget"},{"issue":"8","key":"927_CR32","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1182\/blood.V87.8.3514.bloodjournal8783514","volume":"87","author":"JW Fay","year":"1996","unstructured":"Fay JW, Wingard JR, Antin JH, Collins RH, Pi\u00f1eiro LA, Blazar BR, et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood. 1996;87(8):3514\u20139.","journal-title":"Blood"},{"issue":"11","key":"927_CR33","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/bmt.2012.59","volume":"47","author":"M Skeens","year":"2012","unstructured":"Skeens M, Pai V, Garee A, Termuhlen AM, Bajwa RPS, Gross TG, et al. Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. Bone Marrow Transplant. 2012;47(11):1415\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"927_CR34","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/sj.bmt.1705481","volume":"38","author":"MP Hendriks","year":"2006","unstructured":"Hendriks MP, Blijlevens NMA, Schattenberg AVMB, Burger DM, Donnelly JP. Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2006;38(7):521\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"927_CR35","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1177\/1078155220970608","volume":"27","author":"JA Engle","year":"2021","unstructured":"Engle JA, Wasko JA, Rogosheske J, Defor TE, Rashidi A. Comparison of continuous versus intermittent infusion cyclosporine and impact on transplant related outcomes in allogeneic transplant recipients. J Oncol Pharm Pract. 2021;27(8):1835\u201341.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"927_CR36","first-page":"311","volume":"86","author":"G Dotti","year":"2001","unstructured":"Dotti G, Gaspari F, Caruso R, Perico N, Remuzzi G, Barbui T, et al. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. Haematologica. 2001;86(3):311\u20135.","journal-title":"Haematologica"},{"issue":"5","key":"927_CR37","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0041-1345(98)00385-6","volume":"30","author":"KR Schultz","year":"1998","unstructured":"Schultz KR, Nevill TJ, Toze CL, Corr T, Currie C, Strong DK, et al. The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation. Transplant Proc. 1998;30(5):1668\u201370.","journal-title":"Transplant Proc"},{"issue":"4","key":"927_CR38","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1365-2125.2011.04116.x","volume":"73","author":"AJ Wilhelm","year":"2012","unstructured":"Wilhelm AJ, de Graaf P, Veldkamp AI, Janssen JJWM, Huijgens PC, Swart EL. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. Br J Clin Pharmacol. 2012;73(4):553\u201363.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"927_CR39","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1177\/1078155220970608","volume":"27","author":"JA Engle","year":"2020","unstructured":"Engle JA, Wasko JA, Rogosheske J, Defor TE, Rashidi A. Comparison of continuous versus intermittent infusion cyclosporine and impact on transplant related outcomes in allogeneic transplant recipients. J Oncol Pharm Pract. 2020;27(8):1835\u201341.","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"927_CR40","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1097\/00007890-199912270-00003","volume":"68","author":"M Cantarovich","year":"1999","unstructured":"Cantarovich M, Elstein E, de Varennes B, Barkun JS. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation. 1999;68(12):1839\u201342.","journal-title":"Transplantation"},{"issue":"6","key":"927_CR41","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1097\/00007890-200203270-00022","volume":"73","author":"G Levy","year":"2002","unstructured":"Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation. 2002;73(6):953\u20139.","journal-title":"Transplantation"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00927-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00927-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00927-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T06:49:30Z","timestamp":1738824570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00927-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00927-y","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"30 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No funding was received for conducting this study or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The datasets used and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Faculty of Pharmacy Ethics Committee at Ain Shams University, with a serial number of 70.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients signed written informed consent before enrollment (NCT04575779).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Shaymaa M.M. El-Awady, Amal M El Afifi, Rania Afifi, Nagwa A. Sabri and Marwa Adel Ahmed contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Shaymaa M.M. El-Awady and Marwa Adel Ahmed. The first draft of the manuscript was written by Shaymaa M.M. El-Awady, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}